Journal on Infectious Diseases - BJSTR Journal

Abstract

With the development of surgical methods and pharmaceutical preparations, more patients with benign end-stage lung disease can receive treatment of lung transplants. Not only the number of surgeries has increased to 4,000 per year, but also the survival time has been growing longer. Ten years ago, a lot of medical experts thought that post-transplant #lymphoproliferative disease was a rare disease, but this disease has received more and more attention because of increasing of surgeries. PTLD is a serious and rare post-transplant complication. Compared with other organ transplants, the incidence of heart, lung, and heart lung transplantation is extremely high. The 5-year survival rate is 29%, and the median survival period is 10month. Risk factors for morbidity are related to the use of #immunosuppressive agents, viral infections, type of transplanted organ, gender, age et al. This article will describe the incidence, risk factors, #pathogenic mechanism, treatment methods and latest research progress of lymphoproliferative diseases after lung transplantation recently by providing new ideas on hotspots. Lung transplantation is the only effective way to treat benign lung disease of end-stage. #Vladimir performed lung transplant surgery on animals for the first time 70 years ago epically [1]. Soon after, Hardy did the first human lung transplantation 12 years later [2]. But patient only lived 42 days after the transplant by limiting to the development of surgical techniques and drugs. The emergence of #immunosuppressants represented by #cyclosporine (CsA) in 1983 significantly pulled the survival rate after lung transplantation to a new level. Afterwards, the median survival time after transplantation can reach 5.3 years [3]. Nowadays there are about 4,000 lung transplants per year, including 200 in China. Most of medical experts initially thought that Post-transplant lymphoproliferative disorders (PTLD) was a rare disease, which was been known as a mega misunderstanding presently by discovering from the results of research in the last decade and the increase in surgical patients as well. Immunosuppression and Epstein-Barr virus (EBV) infection are two the most relevant risk factors about PTLD [4]. This article will elaborate advances in research on posttransplant #lymphoproliferative disorders after lung transplantation in recent years and put forward prospects at the same time.

For more articles on BJSTR Journal please click on https://biomedres.us/

 For more  Infectious diseases Articles on BJSTR

https://biomedres.us/fulltexts/BJSTR.MS.ID.001651.php 

 

Research Progress on Lymphoproliferative Diseases after Lung Transplantation by Jun Chen in BJSTR